% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • chevymalibu1966 chevymalibu1966 Oct 15, 2003 3:48 PM Flag

    asked about 40 vs. 31%

    that's the point is either the study/test has a high (erroneous) placebo effect or the drug doesn't work (well).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "The Phase III trial to determine if Antegren� (natalizumab) induces remission in moderate to severe Crohn's disease, known as ENACT-1, is now completed. Elan Corporation announced on Thursday, July 24 that the trial did not meet the primary endpoint of response, which was defined as a 70 point drop in the Crohn's Disease Activity Index (CDAI) at week 10. This result appears to be due to a larger than expected placebo response rate, A PHENOMENON seen in other Crohn's disease trials over the past few years..."

      from CCFA

18.12+0.2000(+1.12%)Dec 18 3:59 PMEST